Ga-prostate-specific membrane antigen 11 (PSMA) PET/CT imaging accurately depicts metastatic prostate adenocarcinoma (PCa). Pulmonary metastases of PCa are often overlooked on follow-up imaging in patients after initial treatment and following androgen deprivation therapy. Here we present a rare case of biopsy-proven PCa pulmonary metastasis with a ground-glass appearance. The increased PSMA expression and the evolving CT features of the solid component of the ground-glass nodule detected by PSMA PET/CT imaging led to surgical resection and PET/CT-guided therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000002499 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy.
J Pers Med
December 2024
Department of Radiology, University Hospital Tuebingen, 72076 Tübingen, Germany.
: Current guidelines recommend Cisplatin/Gemcitabine/Durvalumab as first-line treatment for inoperable or recurrent cholangiocarcinoma (CCA). Molecular tumor boards (MTB) have the expertise to support organ-specific tumor boards with evidence-based treatment recommendations for subsequent lines of treatment, based on genomic tumor data and scientific evidence. This study evaluates the adoption of an MTB at a comprehensive cancer center in Germany and whether actionable genetic alterations are associated with specific imaging phenotypes.
View Article and Find Full Text PDFTreatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases.
Curr Issues Mol Biol
November 2024
Internal Medicine Clinic "Akta Medica", 11000 Belgrade, Serbia.
Lung cancer represents the most common cause of cancer-related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases have worse prognosis, with an overall survival (OS) from three to six months. The majority of them have a poor response to chemotherapy, and the data are controversial regarding the response to immunotherapy.
View Article and Find Full Text PDFThe Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer.
Curr Oncol
December 2024
Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.
Non-small cell lung cancer (NSCLC) is a major cause of mortality in Canada, with many patients presenting with metastatic disease. The oligometastatic state (OM-NSCLC) may be amenable to cure using aggressive local consolidative therapies. Stereotactic body radiotherapy (SBRT), which entails the utilization of a high dose of radiation in one or few fractions, has many benefits in this setting, including its applicability in varied patient populations to ablate lesions in varied anatomical locations.
View Article and Find Full Text PDFEducation and Training Needs of Health Care Professionals in the Philippines Encountering Patients with Lung Oligometastatic Cancers.
Curr Oncol
December 2024
Department of Radiation Oncology, Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON M5G 2M9, Canada.
This study aimed to examine the education and training needs of health care practitioners (HCPs) in the Philippines who encounter lung oligometastatic cancer patients. Lung oligometastatic disease is among the most common sites for cancer spread and has the most established practices for treating oligometastases. A modified version of the Hennessy-Hicks Training Needs Assessment Questionnaire was administered online to HCPs working in private and public centers in the Philippines.
View Article and Find Full Text PDFPlanned Abscopal Effect with Concurrent Pembrolizumab and Ablative Radiotherapy to Pulmonary Metastasis: A Case Report and Review of the Literature.
Curr Oncol
December 2024
Department of Radiation Oncology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi 60002, Taiwan.
Most abscopal effects are reported as sporadic and unpredictable events following radiotherapy at symptomatic sites. Herein, we report a case in which a planned abscopal effect was induced following deliberate radiotherapy and concurrent systemic immunotherapy. A 53-year-old man with a combined positive score ≥10 developed extensive metastatic bladder cancer after progressing on conventional chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!